Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › PathoFinder Obtains CE Mark for Two Multiplex SARS-CoV-2 MDx Tests

PathoFinder Obtains CE Mark for Two Multiplex SARS-CoV-2 MDx Tests

Nov 19, 2020
|
staff reporter

NEW YORK – Dutch molecular diagnostics developer PathoFinder has received CE IVD marking for two multiplex PCR tests for SARS-CoV-2 and other respiratory pathogens.

Specifically, the Maastricht-based firm obtained CE marking for the RespiFinder 2Smart kit for SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS-CoV) testing, as well as for the RealAccurate Quadriplex (RAQ) Flu/COVID-19 PCR kit.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

What's Popular?

In PCR

  1. Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

  2. CDC Study Finds Abbott BinaxNow SARS-CoV-2 Antigen Test Less Sensitive Than PCR, But Still Useful

  3. Molzym, Fraunhofer Developing Rapid Direct-From-Sample Sepsis Diagnostic Platform and Test

    Premium

  4. Lucira Health Files for $115M IPO

  5. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.